76. Pituitary gonadotropin secretion hyperthyroidism Clinical trials / Disease details
Clinical trials : 28 / Drugs : 46 - (DrugBank : 14) / Drug target genes : 6 - Drug target pathways : 19
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-004494-16-Outside-EU/EEA (EUCTR) | 03/12/2014 | A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature puberty | A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty | Central Precocious Puberty MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: trade name depends on the source of the product INN or Proposed INN: LEUPRORELIN ACETATE Trade Name: trade name depends on the source of the product’ INN or Proposed INN: LEUPRORELIN ACETATE | Abbvie previously known as Abbott | NULL | NA | Female: yes Male: yes | 72 | United States;Puerto Rico |